Vantage logo

Roxadustat moves on to the regulators

A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…

Vantage logo

Reneuron’s reinvention falters

More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.